Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

We'll know more about the company's medium-term prospects by the end of the year.

Incyte posted first-quarter revenue and earnings well above analyst expectations, while Intellia reported historic Phase 3 success for its in vivo CRISPR therapy. These developments lifted sentiment ...

The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial ...

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets ...

The precision fermentation market size is expected to be worth USD 75.76 billion by 2035 from USD 6.89 billion in 2026 with a ...

A looming $300 billion patent cliff by 2030 is spurring a surge in biotech M&A, with March 2026 alone seeing $31.5 billion in deals. Analysts highlight CRISPR Therapeutics, Intellia Therapeutics, and ...

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...

Artificial intelligence (AI) is slowly changing and reshaping industries, from banking to telecom. The technology will likely make many jobs obsolete. Some of the corporations leading this revolution ...